Abstract

Clostridioides difficile is a Gram-positive, anaerobic, spore-forming bacillus. It is isolated in 80% of the stools of children and infants and in 3% of healthy adults. It causes gastrointestinal tract infections and affects patients who make prolonged use of antibiotics. It causes C. difficile colitis with symptoms ranging from diarrhoea to pseudomembranous colitis to toxic megacolon. The main virulence factors of C. difficile are toxin A, toxin B, and binary toxin. It is one of the most common nosocomial infections but in recent years, however, many infections have also been found at the community level. They are associated not only with a high risk of mortality but also with a prolongation of hospital stay. One of the critical aspects of C. difficile infections is also represented by the high frequency of relapses. Consequently, the economic impact is significant. Specific situations constitute risk factors for infection, such as exposure to antibiotic therapy in the previous months, in particular fluoroquinolones, third-generation cephalosporins, clindamycin, repeated hospitalizations in healthcare facilities, including long-term care, as well as the patient's clinical conditions such as comorbidities, age >65, chemotherapy and immunosuppressive treatments, recent surgery of any type, and pump inhibitor therapy. Treatment protocols will be described in the paper.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.